

# Vaccines and Global Health: The Week in Review 06 April 2024 :: Issue 745 Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <a href="https://centerforvaccineethicsandpolicy.net">https://centerforvaccineethicsandpolicy.net</a>. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director

Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

**Request email delivery of the pdf:** If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

**Support this knowledge-sharing service:** Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click <u>here</u> to donate and thank you in advance for your contribution.

## Contents [click to move among sections]

- :: Milestones, Perspectives
- :: <u>WHO</u>
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers
- :: Think Tanks

## Milestones, Perspectives

::::::

## WHO calls for action to uphold right to health amidst inaction, injustice and crises

On the anniversary of its founding, the Organization urges countries to invest, tackle discrimination and intolerance, and expand equitable access to quality health services

5 April 2024 News release

To mark World Health Day (7 April), the World Health Organization (WHO) is running the "My health, my right" campaign to champion the right to health of everyone, everywhere. The campaign advocates for ensuring universal access to quality health services, education, and information, as well as safe drinking water, clean air, good nutrition, quality housing, decent working and environmental conditions, and freedom from discrimination.

All around the world, the core challenges consistently compromising the right to health are political inaction coupled with a lack of accountability and funding, compounded by intolerance, discrimination and stigma. Populations facing marginalization or vulnerability suffer the most, such as people who live in poverty, are displaced, are older or live with disabilities.

While inaction and injustice are the major drivers of the global failure to deliver on the right to health, current crises are leading to especially egregious violations of this right. Conflicts are leaving trails of devastation, mental and physical distress, and death.

The burning of fossil fuels is simultaneously driving the climate crisis and violating our right to breathe clean air. The climate crisis is in turn causing extreme weather events that threaten health and well-being across the planet and strain access to services to meet basic needs.

Everyone deserves access to quality, timely and appropriate health services, without being subjected to discrimination or financial hardship. Yet, in 2021, 4.5 billion people, more than half of the world's population, were not covered by essential health services, leaving them vulnerable to diseases and disasters. Even those who do access care often suffer economically for it, with about 2 billion people facing financial hardship due to health costs, a situation that has been worsening for two decades.

To expand coverage, an additional <u>US\$ 200–328 billion a year is needed globally</u> to scale up primary health care in low- and middle-income countries (i.e. 3.3% of national forecast GDP). Progress has shown to be possible where there is political will. Since 2000, 42 countries, representing all regions and income levels, succeeded in improving both health service coverage and protection against catastrophic health spending.

"Realizing the right to health requires governments to pass and implement laws, invest, address discrimination and be held accountable by their populations," said WHO Director-General Dr Tedros Adhanom Ghebreyesus. "WHO is working with governments, partners and communities to ensure the highest attainable standard of health, as a fundamental right for all people, everywhere."

The right to health is enshrined within the WHO Constitution, and at least 140 countries recognize the right to health in their national constitutions. But recognition alone is not enough, which is why WHO supports countries to legislate the right to health across sectors and integrate human rights into health policies and programmes. The aim of this support is to make health services available, accessible and responsive to the needs of the populations they serve and to increase community participation in health decision-making.

On this World Health Day and beyond, WHO is calling for governments to make meaningful investments to scale up primary health care; to ensure transparency and accountability; and to meaningfully involve individuals and communities in decision-making around health. **Recognizing the interdependence between the right to health and other fundamental rights, the campaign includes calls to action on finance, agriculture, environment, justice, transport, labour and social affairs.** 

Individuals, communities and civil society have long defended their right to health, improving access to health care services by breaking down barriers and advocating for equity. WHO urges the public to know, protect and promote their health rights, including those related to safe and quality care, zero discrimination, privacy and confidentiality, information, bodily autonomy, and decision-making.

::::::

Message by the Director of the Department of Immunization, Vaccines and Biologicals at WHO - March 2024

5 April 2024 Departmental news

::::::

#### Cholera

## Global deployment of rapid diagnostic tests to boost fight against cholera

- More than 1.2 million cholera rapid diagnostic tests will be shipped to 14 countries in largest-ever global deployment, with the first shipment landing today in Malawi.
- This first official deployment of tests through Gavi, the Vaccine Alliance, will improve timely
  detection and monitoring of outbreaks, effectiveness of vaccination campaigns in
  response to current outbreaks, and targeting of future preventive vaccination efforts.
- The global cholera rapid diagnostic test procurement programme is a collaboration between Gavi, WHO, UNICEF, FIND, and other partners.

5 April 2024

News release Geneva/New York

The arrival of rapid diagnostic test (RDT) kits for cholera in Malawi today signals the start of a global programme that will see more than 1.2 million tests distributed to 14 countries at high risk for cholera over the next several months. Countries that will receive kits in the coming weeks in this largest-ever global deployment include those currently severely impacted by cholera outbreaks, such as Ethiopia, Somalia, Syria, and Zambia. **This programme will improve the timeliness and accuracy of outbreak detection and response by boosting routine surveillance and testing capacity and helping rapidly identify probable cholera cases.** Critically, it will also help countries monitor trends and build an evidence base for future preventive programmes, supporting the achievement of national cholera control and elimination targets.

The global cholera diagnostics programme is funded and coordinated by <u>Gavi</u>, the <u>Vaccine Alliance</u> (Gavi), with procurement and delivery to countries led by <u>UNICEF</u>, and undertaken in collaboration

with the Global Task Force on Cholera Control (GTFCC), and <u>WHO</u>. It was developed in partnership with <u>FIND</u>, who led development of a target product profile describing the required characteristics of cholera RDTs, and other organizations. These initial shipments signal the start of the programme, which aims to see partners deploy RDTs to additional countries that have expressed interest in the future. Long-term sustainability of the programme depends on successful fundraising for Gavi's next strategic period, from 2026 to 2030.

Through this effort, rapid diagnostic tests from two manufacturers – that have to-date been supplied via WHO and UNICEF for use in outbreak response – will now be used routinely for cholera surveillance. Pilot studies across the Democratic Republic of the Congo (DRC), Niger and Nepal, funded by Gavi and led by the United States Centers for Disease Control and Prevention (CDC), Johns Hopkins University (JHU) and Epicentre/ Médecins Sans Frontières have helped increase understanding of effective rapid testing strategies. Preliminary insights from these studies, which are still ongoing, have helped inform programme design – making the rollout of these tests at scale more effective...

While global oral cholera vaccine supply has increased eighteen-fold between 2013 and 2023, the large and sustained spike in demand compared to the current availability has put a strain on the global stockpile. Preventive vaccination campaigns have had to be delayed to preserve doses for emergency outbreak response efforts. Recurring outbreaks in countries where emergency vaccination campaigns have already been implemented further highlight the need for improved speed and accuracy in identifying areas with new or persistent transmission – enabling these areas to be targeted during initial outbreak response efforts.

In 2021, the Gavi Board approved US\$ 55 million in funding to support a diagnostics programme between 2022 and- 2025 across cholera, yellow fever, measles, rubella, meningococcal meningitis and typhoid — with the aim to improve disease surveillance, outbreak detection and response and the design of preventive programmes. Gavi then opened a cholera diagnostics application window in June 2023 — which is still open — and so far 14 countries have submitted applications and been approved by an Independent Review Committee of experts. In 2023, Gavi also launched a preventive cholera vaccination programme, to support countries with long-term cholera control — a strategy that has successfully led to a decrease in outbreaks of diseases such as yellow fever and meningitis...

"We are experiencing an unprecedented multi-year upsurge in cholera cases worldwide, and today's announcement provides a critical boost in the fight against the disease. The rise in infections is being driven by continued gaps in access to safe water and sanitation, and our inability to reach vulnerable communities that are being put further at risk by climate change, conflict and displacement," said Aurélia Nguyen, Chief Programme Officer at Gavi, the Vaccine Alliance. "Routine use of diagnostics will bolster cholera surveillance in impacted countries, and must be leveraged to better target vaccination efforts, which play a critical role in multisectoral cholera prevention and control programmes."

"Despite cholera being preventable and easily treatable, children continue to suffer from this potentially fatal disease. This is why we are working with partners on all fronts and in novel ways to stem outbreaks," said Leila Pakkala, Director of UNICEF Supply Division. "Surveillance diagnostics help pinpoint hotspots with great precision. This allows partners to target cholera vaccines to exactly the time and place where the limited supply will save the most lives."...

Note to editors

The 14 countries that have received Gavi IRC approvals so far are: Cameroon, Democratic Republic of the Congo, Ethiopia, Malawi, Mozambique, Nepal, Nigeria, Pakistan, Sierra Leone, Somalia, Syria, Uganda, Zambia, and Zimbabwe.

#### **Avian Influenza**

#### **High Pathogenicity Avian Influenza in Cattle**

Statement - World Organisation for Animal Health Published on 5 April 2024

The ongoing spread of High Pathogenicity Avian Influenza (HPAI) in different regions of the world, alongside the recent detections of cases in cattle, is raising concerns within the international community.

While HPAI primarily affects poultry and wild birds, avian influenza can occasionally be transmitted to mammals, including humans. In the last two years, an increasing number of H5N1 avian influenza cases have been <u>reported</u> in terrestrial and aquatic mammalians animals.

The recently <u>reported detections of HPAI</u> in dairy <u>cattle in the United States of America</u>, showing clinical signs such as decreased lactation, reduced appetite, lethargy, fever and dehydration, have raised concerns since such infections of cattle could indicate an increased risk of H5N1 viruses becoming better adapted to mammals, and potentially spilling over to humans and other livestock.

Initial investigations so far have revealed no specific adaptation to either humans or mammals. Regardless, several studies are being carried out to further explore the virulence and transmissibility of these viruses, including among cattle, and to assess the risk of transmission to animals and humans, which is currently considered very low.

In collaboration with its <u>Reference Centres</u>, <u>OFFLU</u> networks of experts and Members, the World Organisation for Animal Health (WOAH) is closely monitoring the situation to assess the risks to animals and humans. Timely and transparent reporting is crucial to maintain a good understanding of the disease situation and prevent any type of misinformation or disinformation.

WOAH reminds its 183 Members that, based on the information currently available, restrictions on the movement of healthy cattle and their products are not recommended unless justified by an import risk analysis conducted according to the <u>WOAH Terrestrial Animal Health Code Chapter 2.1.</u>

::::::

## <u>Understanding avian influenza pandemic drivers crucial in reducing risks to human</u> health

3 Apr 2024

In a joint report released today, the European Centre for Disease Prevention and Control (ECDC) and the European Food Safety Authority (EFSA) outline the contributing drivers for influenza A(H5N1) viruses to acquire the ability to spread efficiently among humans, thereby increasing their pandemic potential. The report also addresses which mitigation measures could be implemented in animals and humans to reduce the risk to human health.

The report examines intrinsic drivers related to virus characteristics or host susceptibility. It also discusses extrinsic drivers which may increase exposure of

mammals and humans to avian influenza viruses, thereby stimulating mutation and adaptation to mammals. Such drivers include the ecology of host species such as wildlife, human activities like farming practices and use of natural resources, climatic and environmental factors.

Influenza viruses remain prevalent among wild bird populations in the EU/EEA, leading to significant illness and death in birds. Transmission between bird and mammal species has been observed, including in fur animal farms where outbreaks have been reported. Angeliki Melidou, ECDC Principal Expert on Respiratory Viruses, said: "Transmission from infected birds to humans remains a rare event, with no confirmed human infection identified in the EU/EEA. Nonetheless, the potential for avian influenza viruses to adapt to humans and cause a pandemic remains a concern. Ongoing vigilance, preparedness efforts and an increased understanding of underlying drivers is therefore crucial"...

## <u>Drivers for a pandemic due to avian influenza and options for One Health mitigation measures</u> - Report

Avian influenza viruses (AIV) remain prevalent among wild bird populations in the European Union and European Economic Area (EU/EEA), leading to significant illness in and death of birds. European Centre for Disease Prevention and Control 03 April 2024

PDF: "<u>Drivers for a pandemic due to avian influenza and options for One Health mitigation measures</u> - EN - [PDF-376.81 KB]

Executive summary

Transmission between bird and mammal species has been observed, particularly in fur animal farms, where outbreaks have been reported. While transmission from infected birds to humans is rare, there have been instances of exposure to these viruses since 2020 without any symptomatic infections reported in the EU/EEA. However, these viruses continue to evolve globally, and with the migration of wild birds, new strains carrying potential mutations for mammalian adaptation could be selected. If avian A(H5N1) influenza viruses acquire the ability to spread efficiently among humans, large-scale transmission could occur due to the lack of immune defences against H5 viruses in humans.

The emergence of AIV capable of infecting mammals, including humans, can be facilitated by various drivers. Some intrinsic drivers are related to virus characteristics or host susceptibility. Other drivers are extrinsic and may increase exposure of mammals and humans to AIV thereby stimulating mutation and adaptation to mammals. Extrinsic drivers include the ecology of host species, such as including wildlife, human activities like farming practices and the use of natural resources, climatic and environmental factors.

One Health measures to mitigate the risk of AIV adapting to mammals and humans focus on limiting exposure and preventing spread. Key options for actions include enhancing surveillance targeting humans and animals, ensuring access to rapid diagnostics, promoting collaboration between animal and human sectors, and considering the implementation of preventive measures such as vaccination of poultry.

Effective communication to different involved target audiences should be emphasised, as well as strengthening veterinary infrastructure, enforcing biosecurity measures at farms, and reducing wildlife contact with domestic animals. Careful planning of poultry and fur animal farming, especially in areas with high waterfowl density, is highlighted for effective risk reduction.

Polio	– PHEIC
::::::	
::::::	
::::::	

#### Polio this week as of 03 Apr 2024 - GPEI

Headlines

:: Iraq has achieved a major milestone, becoming the first polio transition priority country to take on all responsibility for sustaining polio functions with a commitment to provide full domestic funding. Dr Hanan Balkhy, WHO Regional Director for the Eastern Mediterranean, commended Irag's public health win and the positive impact it will yield: "I would like to congratulate Iraq for the achievement of polio transition in full in a considerably short period of time. This is a great step towards enhancing the health system's resilience and regaining its capabilities to better serve the Iragi population, making the best use of the polio programme assets."

:: In Eradicating Polio is Possible: Stories of Resilience and Hope the United Nations Foundation interviews polio survivors and a UNICEF polio communications officer. The piece focuses on personal experiences with polio and ongoing commitment to eradication.

:: This scientific paper looks at the journey of novel oral polio vaccine type 2 (nOPV2) from development through rollout and WHO prequalification. The piece presents nOPV2 as an example of how scientific advances and innovative tools can be applied to combat global health emergencies.

## Summary of new polioviruses this week, cases and positive environmental isolates:

- Afghanistan: one WPV1 case
- Pakistan: 12 WPV1-positive environmental samples
- Nigeria: three cVDPV2 cases and two cVDPV2-positive environmental samples

:::::: ::::::

#### Contents [click to move among sections]

- :: Milestones, Perspectives
- :: WHO
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers

:::::: ::::::

#### WHO & Regional Offices [to 06 Apr 2024]

https://www.who.int/news

Selected News/Announcements/Statements

6 April 2024 Statement

Six months of war leave Al-Shifa hospital in ruins, WHO mission reports

5 April 2024 News release

WHO calls for action to uphold right to health amidst inaction, injustice and crises

5 April 2024 News release

Global deployment of rapid diagnostic tests to boost fight against cholera

5 April 2024 Departmental news

Message by the Director of the Department of Immunization, Vaccines and Biologicals at WHO - March 2024

4 April 2024 Departmental news

## New law and policy portal launched to advance implementation of the Global health and care workers compact

4 April 2024 Departmental news

The Self-Care Wheel: an award-winning innovation to advance sexual and reproductive health and rights

3 April 2024 Departmental news

Stakeholders convene in Uganda on responsible use of the life sciences

2 April 2024 News release

WHO unveils a digital health promoter harnessing generative AI for public health

1 April 2024 Departmental news

New WHO guidance promotes fair and ethical management of international health worker migration

::::::

## **WHO Regional Offices**

Selected Press Releases, Announcements

## **WHO African Region**

No new digest content identified.

## **WHO Region of the Americas PAHO**

:: 5 Apr 2024

## World Health Day: PAHO reaffirms its commitment to the right to health for all people

Washington, DC, 5 April 2024 (PAHO)- For World Health Day, celebrated on April 7, the Pan American Health Organization (PAHO) reiterated its commitment to the right to health for all people, without discrimination of any kind."At PAHO, we strive to fulfill this right to health by working with our Member States to advance universal health for all,...

:: 4 Apr 2024

## **PAHO launches open call for Strategic Advisory Groups**

Strategic Advisory Groups will advise the Organization on a variety of technical issues, including disease elimination, mental health, climate change, and maternal mortality, among others. Washington D.C. 4 April 2024—The Director of the Pan American Health Organization (PAHO), Dr. Jarbas Barbosa, launched 12 open calls for experts to join the...
:: 2 Apr 2024

## **Countries of the Americas report progress towards healthy aging**

Washington, DC, April 2, 2024 (PAHO) - The Pan American Health Organization (PAHO) today released a progress report revealing advances in policies and actions to promote healthy aging in the region, despite the challenges the world has faced since 2020. The 2023 Progress Report of the Decade of Healthy Aging (2021-2030) highlights that increases in...

## **WHO South-East Asia Region SEARO**

No new digest content identified.

## **WHO European Region EURO**

No new digest content identified.

#### WHO Eastern Mediterranean Region EMRO

No new digest content identified.

## **WHO Western Pacific Region**

:: 5 April 2024 Media release

WHO urges action to fully realize people's right to health in the Western Pacific

::::::

### **WHO - Emergency situation reports**

Latest WHO official reports for emergency situations. 3 April 2024

WHO's Operational Update on Health Emergencies - March 2024

2 April 2024

## Public Health Situation Analysis: Sudan Conflict (03 April 2024)

**Overview** 

Humanitarian needs across Sudan are at record highs with 24.8 million people, or every second person, needing humanitarian assistance in 2024. This is 9 million more than in 2023. People have been forced to flee their homes due to the dire humanitarian situation and the destruction of essential infrastructure, such as roads, hospitals, medical facilities, and schools, as well as power, water, and communications services. The number of people displaced by the conflict continues to increase, with 8.1 million people fleeing their homes in Sudan. Approximately 6.3 million people are displaced within Sudan and another 1.8 million people who fled abroad.

::::::

## **Disease Outbreak News (DONs)**

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

## 2 April 2024 | Avian Influenza A(H5N1) - Viet Nam

Situation at a Glance

The World Health Organization (WHO) was notified about a case of human infection with an influenza A(H5N1) virus on 25 March 2024 by the national authorities of Viet Nam. The patient, who had no underlying medical conditions, developed symptoms on 11 March and died on 23 March. Exposure to birds was ascertained to have taken place in the third week of February...

::::::

#### **Weekly Epidemiological Record**

https://www.who.int/publications/journals/weekly-epidemiological-record Vol. 99, No. 13, pp. 147–162 **29 March 2024** 

https://iris.who.int/bitstream/handle/10665/376354/WER9913-eng-fre.pdf

:: Genetic and antigenic characteristics of zoonotic influenza A viruses and development of candidate vaccine viruses for pandemic preparedness

::::::

## **New WHO Publications**

https://www.who.int/publications/i Selected 5 April 2024

Supporting Marburg virus disease outbreak response through online learning

2 April 2024

<u>Strategy for optimizing national routine health information systems: strengthening routine health information...</u>

2 April 2024

**Universal newborn screening: Implementation guidance** 

1 April 2024

Medicines for HIV, viral hepatitis, and sexually transmitted infections in low- and middle-income countries: forecasts...

::::::

**USA – HHS, FDA, CDC** 

#### **HHS**

*News* 

## **HHS Releases White Paper Focused on Preventing Drug Shortages**

April 2, 2024 News Release

Today, the U.S. Department of Health and Human Services (HHS) released a white paper highlighting steps HHS has taken to prevent and mitigate drug shortages and proposing additional solutions for policymakers to consider. Drug shortages have occurred in the nation's health care system for several decades, largely due to market failures and misaligned incentives. With today's white paper, HHS offers solutions and stands ready to work with Congress to ensure no patient faces the devastating consequences of drug shortages or goes without needed medicines.

#### **FDA**

<u>Press Announcements</u> No new digest content identified.

#### **FDA VRBPAC**

Advisory Committee Calendar

<u>Vaccines and Related Biological Products Advisory Committee May 16, 2024 Meeting Announcement - 05/16/2024</u>

## **CDC/ACIP [U.S.]** [to 06 Apr 2024]

http://www.cdc.gov/media/index.html

Latest News Releases

<u>Highly Pathogenic Avian Influenza A (H5N1) Virus Infection Reported in a Person in the U.S.</u>

CDC's Risk Assessment for the General Public Remains Low

April 1, 2024 —A person in the United States has tested positive for <a href="https://night.com/highly-pathogenic avian">highly-pathogenic avian</a> influenza (HPAI) A(H5N1) virus ("H5N1 bird flu"), as reported by Texas and confirmed by CDC. This person had exposure to dairy cattle in Texas presumed to be infected with HPAI A(H5N1) viruses. The patient reported eye redness (consistent with conjunctivitis), as their only symptom, and is recovering. The patient was told to isolate and is being treated with an antiviral drug for flu. This infection does not change the H5N1 bird flu human health risk assessment for the U.S. general public, which CDC considers to be low. However, people with close or prolonged, unprotected exposures to infected birds or other animals (including livestock), or to environments contaminated

by infected birds or other animals, are at greater risk of infection. CDC <u>has interim recommendations</u> for prevention, monitoring, and public health investigations of HPAI A(H5N1) viruses.

CDC is working with state health departments to continue to monitor workers who may have been in contact with infected or potentially infected birds/animals and test those people who develop symptoms. CDC also has <u>recommendations for clinicians</u> on monitoring, testing, and antiviral treatment for patients with suspected or confirmed avian influenza A virus infections...

### **ACIP Meetings**

Next ACIP Meeting
June 26-28

## **MMWR Weekly**

https://www.cdc.gov/mmwr/index2023.html

April 4, 2024 / No. 13

PDF of this issue

- Surveillance To Track Progress Toward Polio Eradication Worldwide, 2022–2023
- <u>Federal Retail Pharmacy Program Contributions to Bivalent mRNA COVID-19 Vaccinations Across Sociodemographic Characteristics United States, September 1, 2022–September 30, 2023</u>

::::::

### **Europe**

## **European Medicines Agency [EMA]**

https://www.ema.europa.eu/en/news News & Press Releases No new digest content identified.

#### **European Centre for Disease Prevention and Control**

https://www.ecdc.europa.eu/en

News/Updates/Reports/Publications [Selected]

Outbreak of mpox caused by Monkeypox virus clade I in the Democratic Republic of the Congo

5 Apr 2024

## <u>Understanding avian influenza pandemic drivers crucial in reducing risks to human health</u>

3 Apr 2024

Surveillance and monitoring

## <u>Drivers for a pandemic due to avian influenza and options for One Health mitigation measures</u>

3 Apr 2024

Avian influenza viruses (AIV) remain prevalent among wild bird populations in the European Union and European Economic Area (EU/EEA), leading to significant illness in and death of birds.

::::::

Africa CDC [to 06 Apr 2024]

https://africacdc.org/

Press Releases, Statements [Selected]

## Addressing Regulatory Challenges to Advance Local Manufacturing in Africa 3 April 2024

Local manufacturing and access to health products represent strategic pillars of the health and security agenda for the African continent. African leaders pledge to increase the share of vaccines, medicines, and diagnostics locally manufactured in Africa to 60% by 2040. This vision will be achieved by establishing a sustainable vaccine development and manufacturing ecosystem underpinned by research and development, intellectual property (IP) and technology transfer, robust regulatory systems, innovative and sustainable financing, strategic partnerships, and commitment by African and global procurement agencies to purchase vaccines produced on the continent...

:::::

#### **China CDC**

http://www.chinacdc.cn/en/

## **National Health Commission of the People's Republic of China** [to 06 Apr 2024]

http://en.nhc.gov.cn/

News

No new digest content identified.

#### National Medical Products Administration – PRC [to 06 Apr 2024]

http://english.nmpa.gov.cn/

News

No new digest content identified.

China CDC

**Weekly Reports: Current Volume (6)** 

2024-04-05 / No. 14

View PDF of this issue

::::::

## Contents [click to move among sections]

:: Milestones, Perspectives

:: WHO

:: Organization Announcements

:: Journal Watch

:: Pre-Print Servers

::::::

## **Organization Announcements**

## Paul G. Allen Frontiers Group [to 06 Apr 2024]

https://alleninstitute.org/news-press/

News

Featured

## **Unraveling the Complexity of the Mammalian Brain**

04.03.2024

Scientists used advanced, single-cell genomics and spatial mapping technologies to reveal this complex and rich cellular landscape.

#### **BMGF - Gates Foundation** [to 06 Apr 2024]

https://www.gatesfoundation.org/ideas/media-center

Press Releases and Statements No new digest content identified.

## **Bill & Melinda Gates Medical Research Institute** [to 06 Apr 2024]

https://www.gatesmri.org/news

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people News: Articles and Publications

**CARB-X** [to 06 Apr 2024]

https://carb-x.org/

News

No new digest content identified.

No new digest content identified.

## **CEPI – Coalition for Epidemic Preparedness Innovations** [to 06 Apr 2024]

http://cepi.net/

## <u>Participants in Nigeria vaccinated in first-ever Phase 2 Lassa fever vaccine clinical trial</u> CEPI 3rd April 2024

- Participants in Nigeria have been vaccinated with a Lassa fever vaccine candidate in the first Phase 2 clinical trial of any Lassa vaccine.
- Lassa fever is a deadly hemorrhagic fever common to West Africa. No approved vaccine currently exists.
- More than 600 participants in Ghana, Liberia, and Nigeria are expected to enrol in the IAVI-sponsored trial, funded by CEPI.

## CIOMS - COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to

06 Apr 2024]

https://cioms.ch/

News; Publications; Events

No new digest content identified.

#### DARPA – Defense Advanced Research Projects Agency [U.S.] [to 06 Apr 2024

https://www.darpa.mil/news

News

5/2024

## **Streamlining Delivery Modalities for Biologic Therapeutics to Improve Patient Outcomes**

Efforts to develop novel biologic therapeutics have provided critical resources to enable warfighter readiness and counter existing and emerging biothreats; however, current delivery modalities limit biologics' efficacy and rapid deployment. The goal of DARPA's new Hermes program is to overcome the challenges associated with broad, intracellular delivery of biologics to diverse cell and tissue types by developing new delivery modalities that provide systemic distribution with limited negative side effects.

#### **Duke Global Health Innovation Center** [to 06 Apr 2024]

https://dukeghic.org/

News

No new digest content identified.

## **EDCTP** [to 06 Apr 2024]

http://www.edctp.org/

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials News

No new digest content identified.

## **Emory Vaccine Center** [to 06 Apr 2024]

http://www.vaccines.emory.edu/ Vaccine Center News No new digest content identified.

#### **European Vaccine Initiative** [to 06 Apr 2024]

http://www.euvaccine.eu/ Latest News, Events No new digest content identified.

## Evidence Aid [to 06 Apr 2024]

Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.

http://www.evidenceaid.org/

Resources [Selected]

## School and community-based interventions for refugee children

Added April 1, 2024

## Evidence-based care for asylum seekers and refugees of the Syrian civil war

Added March 31, 2024

## Sexual and reproductive health experiences of separated young people on the move

Added March 30, 2024

## Fondation Merieux [to 06 Apr 2024]

http://www.fondation-merieux.org/ News, Events No new digest content identified.

Gavi [to 06 Apr 2024] https://www.gavi.org/ News Releases 5 April 2024

## Global deployment of rapid diagnostic tests to boost fight against cholera

- :: More than 1.2 million cholera rapid diagnostic tests will be shipped to 14 countries in largest-ever global deployment, with the first shipment landing today in Malawi.
- :: This first official deployment of tests through Gavi, the Vaccine Alliance, will improve timely detection and monitoring of outbreaks, effectiveness of vaccination campaigns in response to current outbreaks, and targeting of future preventive vaccination efforts.
- :: The global cholera rapid diagnostic test procurement programme is a collaboration between Gavi, WHO, UNICEF, FIND, and other partners.

#### 4 April 2024

## Gavi increases support to reach all children with immunisation in the Central African Republic

- :: Gavi to increase its financial support to strengthen data systems, bolster health workforce and engagement at community level, and foster innovation for enhancing outreach to better identify and reach missed children.
- :: Announcement follows discussions on key priorities with Government and partners during a two-day visit by Gavi CEO Dr Sania Nishtar and senior Gavi leadership to the Central African Republic.
- :: Central African Republic President Faustin-Archange Touadéra: "Investing in prevention is the smartest use of our limited health resources and within this investment, vaccination is the best buy to protect our children. My goal is to ensure everyone is protected against life-threatening diseases even in the hardest to reach regions of our country."
- :: Minister of Health Dr Pierre Somse: "The announcement today will consolidate health system support towards three priority areas which have the maximum potential of impact to serve the needs of our population."

#### **GE2P2 Global Foundation** [to 06 Apr 2024]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements

- :: Vaccines and Global Health: The Week in Review Current edition
- :: Informed Consent: A Monthly Review March 2024
- :: Genomic Medicine Governance, Ethics, Policy, Practice: A Monthly Digest Oct 2023
- :: Public Consultations Watch :: Global Calls for Input/Public Comment 07 March 2024 Issue 14

**GHIT Fund** [to 06 Apr 2024] <a href="https://www.ghitfund.org/newsroom/press">https://www.ghitfund.org/newsroom/press</a> <a href="https://www.ghitfund.org/newsroom/press">Press Releases</a> <a href="https://www.ghitfund.org/newsroom/press">No new digest content identified.</a>

Global Fund [to 06 Apr 2024].

https://www.theglobalfund.org/en/news/

News & Stories

No new digest content identified.

## Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 06 Apr 2024]

https://www.glopid-r.org/news/

News

No new digest content identified.

## Hilleman Laboratories [to 06 Apr 2024]

http://www.hilleman-labs.org/

News & Insights

No new digest content identified.

## **HHMI - Howard Hughes Medical Institute** [to 06 Apr 2024]

https://www.hhmi.org/news

Press Room

No new digest content identified.

## **Human Immunome Project [nee Human Vaccines Project]** [to 06 Apr 2024]

http://www.humanvaccinesproject.org/

News

## A Year in Review: 2023 Impact Report

At the Human Immunome Project, 2023 was a year of transition and great progress. From onboarding new leadership to hosting a global conference, and most importantly, fully articulating our scientific plan, we set the foundation to successfully harness the power of the immune system to improve health for all.

**IAVI** [to 06 Apr 2024]

https://www.iavi.org/

News, Features

Press Releases

## <u>Participants in Nigeria vaccinated in first-ever Phase 2 Lassa fever vaccine clinical trial,</u> sponsored by IAVI

April 4, 2024 The CEPI-funded study will evaluate the safety, tolerability, and immunogenicity of IAVI's single dose Lassa fever vaccine candidate

**INSERM** [to 06 Apr 2024]

https://www.inserm.fr/en/home/

Press Releases

No new digest content identified.

## **International Coalition of Medicines Regulatory Authorities [ICMRA]**

http://www.icmra.info/drupal/en/news

## **ICH - International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use** [to 06 Apr 2024]

https://www.ich.org/page/press-releases News/Pubs/Press Releases [Selective] No new digest content identified.

ICRC [to 06 Apr 2024]
<a href="https://www.icrc.org/en/whats-new">https://www.icrc.org/en/whats-new</a>
What's New [Selected]
No new digest content identified.

#### **IFFIm**

http://www.iffim.org/ Press Releases/Announcements No new digest content identified.

IFRC [to 06 Apr 2024] http://media.ifrc.org/ifrc/news/press-releases/ Press Releases [Selected] No new digest content identified.

Institut Pasteur [to 06 Apr 2024] https://www.pasteur.fr/en/press-area Press Documents No new digest content identified.

#### **ISC / International Science Council** [to 06 Apr 2024]

https://council.science/current/

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

Latest Updates

News

The ISC's Centre for Science Futures secures over one million dollars grant to explore the impacts of AI on science systems in the Global South

The International Development Research Centre (IDRC) of Canada will be supporting the Centre for Science Futures, the ISC's think tank, with a grant of over one million dollars to explore the impacts of AI on science systems in the Global South. 05.04.2024

## **International Union of Immunological Societies (IUIS)**

https://iuis.org/

News/Events [Selected] No new digest content identified.

**IVAC** [to 06 Apr 2024]

https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html

Updates; Events

No new digest content identified.

IVI [to 06 Apr 2024]
<a href="http://www.ivi.int/">http://www.ivi.int/</a>
IVI News & Announcements
No new digest content identified.

## **Johns Hopkins Center for Health Security** [to 06 Apr 2024]

https://centerforhealthsecurity.org/newsroom Center News [Selected] No new digest content identified.

## MSF/Médecins Sans Frontières\_ [to 06 Apr 2024]

http://www.msf.org/ Latest [Selected Announcements] No new digest content identified.

## National Academy of Medicine - USA [to 06 Apr 2024]

https://nam.edu/programs/
News [Selected]
No new digest content identified.

## National Academy of Sciences - USA [to 06 Apr 2024]

https://www.nationalacademies.org/newsroom? News No new digest content identified.

## National Vaccine Program Office - U.S. HHS [to 06 Apr 2024]

https://www.hhs.gov/vaccines/about/index.html *Upcoming Meetings/Latest Updates* June 13-14, 2024

NIH [to 06 Apr 2024] http://www.nih.gov/ New Releases No new digest content identified. PATH [to 06 Apr 2024] https://www.path.org/media-center/ Newsroom No new digest content identified.

## **Sabin Vaccine Institute** [to 06 Apr 2024]

https://www.sabin.org/press/ Latest News & Press Releases No new digest content identified.

## **UNAIDS** [to 06 Apr 2024]

http://www.unaids.org/en

Selected Press Releases/Reports/Statements

Press statement

<u>UNAIDS notes the judgment of the Constitutional Court of Uganda which has struck</u> down certain parts of the Anti-Homosexuality Act, 2023

3 April 2024

## **UNICEF** [to 06 Apr 2024]

https://www.unicef.org/media/press-releases Latest press releases, news notes and statements Press release 05 April 2024

## Global deployment of rapid diagnostic tests to boost fight against cholera

GENEVA/NEW YORK, 5 April 2024 – The arrival of rapid diagnostic test (RDT) kits for cholera in Malawi today signals the start of a global programme that will see more than 1.2 million tests distributed to 14 countries at high risk for cholera over the next several months. Countries that will receive kits in the coming weeks in this largest-ever...

Unitaid [to 06 Apr 2024] https://unitaid.org/ Featured News No new digest content identified.

## **Vaccine Equity Cooperative [nee Initiative]** [to 06 Apr 2024]

https://vaccineequitycooperative.org/news/ News

No new digest content identified.

## Vaccination Acceptance & Demand Initiative [Sabin) [to 06 Apr 2024]

https://www.vaccineacceptance.org/ Announcements, Blog No new digest content identified.

Vaccine Confidence Project [to 06 Apr 2024]

http://www.vaccineconfidence.org/

## **Vaccine Education Center – Children's Hospital of Philadelphia** [to 06 Apr 2024]

http://www.chop.edu/centers-programs/vaccine-education-center

News

No new digest content identified.

## Wellcome Trust [to 06 Apr 2024]

https://wellcome.org/ News. Opinion, Reports No new digest content identified.

#### **The Wistar Institute** [to 06 Apr 2024]

https://www.wistar.org/news/press-releases

Press Releases

No new digest content identified.

## World Bank [to 06 Apr 2024]

http://www.worldbank.org/en/news/all

All News [Selected]

#### **Health and Climate Change**

Climate change: a global health emergency As the global climate crisis escalates, its devastating impacts on human health and well-being will also accelerate. No one anywhere around the globe is beyond...

Date: April 05, 2024 Type: Brief

#### WFPHA: World Federation of Public Health Associations [to 06 Apr 2024]

https://www.wfpha.org/

Blog

#### **GPHW2024: Foreign Affairs and Health Governance: The Rising of Health Diplomacy**

Apr 5, 2024

GPHW2024: Foreign Affairs and Health Governance: The Rising of Health DiplomacyTheme: Enhancing and Democratizing Governance in Global Health Date and Time: 9th April 2024 |15:00-17:00 (CET)

#### World Medical Association [WMA] [to 06 Apr 2024]

https://www.wma.net/news-press/press-releases/

Press Releases

No new digest content identified.

#### **World Organisation for Animal Health** [to 06 Apr 2024]

https://www.oie.int/en/ Press Releases, Statements Statements

#### **High Pathogenicity Avian Influenza in Cattle**

Published on 5 April 2024

The ongoing spread of High Pathogenicity Avian Influenza (HPAI) in different regions of the world, alongside the recent detections of cases in cattle, is raising concerns within the international community...

#### News

## Amid the escalating impact of antimicrobial resistance, the Global Leaders Group calls on UN Member States to take bold and specific action

Published on 5 April 2024

...In a new report released today, the GLG calls on political leaders to make specific commitments at the high-level meeting on AMR to be held at the United Nations General Assembly on 26 September. The GLG report, "Towards specific commitments and action in the response to antimicrobial resistance" urges UN Member States to ensure that adequate, predictable, and sustainable financing is available from domestic and external sources to address AMR, including to tackle the dwindling research and development pipeline for new antibiotics. The GLG proposes that existing financing instruments expand their scope to include AMR and increase investments to support implementation of multisectoral National Action Plans, especially in low- and middle-income countries.

The report notes how accountable, effective and functional multisectoral governance is critical to coordinate a global response to AMR and successfully implement interventions. To achieve this, the GLG proposes an independent panel be established to monitor and report on science and evidence related to AMR to inform advocacy and action and formalising the Quadripartite Joint Secretariat to facilitate collaborative and coordinated action against AMR...

::::::

## ARM [Alliance for Regenerative Medicine] [to 06 Apr 2024]

https://alliancerm.org/press-releases/ Selected Press Releases No new digest content identified.

**BIO** [to 06 Apr 2024] https://www.bio.org/press-releases Press Releases No new digest content identified.

## **DCVMN – Developing Country Vaccine Manufacturers Network** [to 06 Apr 2024]

http://www.dcvmn.org/ News; Upcoming events No new digest content identified.

#### ICBA – International Council of Biotechnology Associations [to 06 Apr 2024]

https://internationalbiotech.org/news/

News

No new digest content identified.

**IFPMA** [to 06 Apr 2024]

https://ifpma.org/

News

Statement 5 Apr 2024

## <u>Biopharmaceutical CEO Roundtable gathers in Athens, focusing on global health challenges and role of pharmaceutical innovation</u>

The Biopharmaceutical CEO Roundtable (BCR), which represents the world's leading biopharmaceutical companies, met in April, Greece, on 3 and 4 April 2024, to discuss global health challenges and public health policies impacting biomedical innovation. 05 April 2024, Athens – The CEOs of leading biopharmaceutical companies met in Athens, Greece, to discuss collaborative solutions that can...

Statement 5 Apr 2024

## Enhanced collaboration between anti-doping agency and big pharma bolsters support for clean sport among athletes

On 3 April 2024 in Athens, the International Federationof Pharmaceutical Manufacturers and Associations (IFPMA) and the World Anti-Doping Agency (WADA) signed a joint letter of intent.

## International Alliance of Patients' Organizations – IAPO [to 06 Apr 2024]

https://www.iapo.org.uk/news Press and media [Selected] No new digest announcements identified.

## **International Generic and Biosimilar Medicines Association [IGBA]**

https://www.igbamedicines.org/

News

No new digest announcements identified.

PhRMA [to 06 Apr 2024]
http://www.phrma.org/
Press Releases
No new digest announcements identified.

::::::

## Vaccines/Therapeutics/Medicines - Selected Developer/Manufacturer Announcements

## **AstraZeneca**

<u>Press Releases</u> \_ - No new digest announcements identified.

## **Bharat Biotech**

Press Releases

## Bharat Biotech and Bilthoven Biologicals B.V. Announce Collaboration to Produce and Supply Oral Polio Vaccines

Hyderabad, India / Netherlands, 2nd April 2024: Bharat Biotech, a global leader in vaccine and biotherapeutic innovation, also the largest manufacturer of oral polio vaccines, and Bilthoven Biologicals B.V., (BBio), a wholly owned subsidiary of Serum Institute of India Private Limited, based

in Netherlands, announced a collaboration today, to further strengthen the production and supply security of Oral Polio Vaccines (OPV).

A requisite Agreement has been signed between BBIL and BBio wherein BBIL will procure drug substances for the production of oral polio vaccines to be supplied within India and globally.

Through this collaboration, BBIL and BBio will jointly obtain the regulatory approvals and licenses required to commercially manufacture OPVs in India for global supplies from drug substances manufactured in the Netherlands at Bilthoven Biologicals...

#### **BioCubaFarma** – Cuba

<u>Últimas Noticias</u> - No new digest announcements identified

## **Biological E**

<u>News</u> - No new digest announcements identified.

#### **BioNTech**

<u>Press Releases</u> - No new digest announcements identified.

## **Boehringer**

<u>Press Releases</u> - No new digest announcements identified.

#### **CanSinoBIO**

<u>News</u> - Website not responding at inquiry

#### **CIGB**

<u>Latest News</u> - No new digest announcements identified.

## Cinnagen

<u>Recent News</u> - No new digest announcements identified.

## **Clover Biopharmaceuticals** – China

<u>News</u> - No new digest announcements identified.

#### Curevac [Bayer Ag – Germany]

<u>News</u>

April 4, 2024

## <u>CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine</u> Development Program in Collaboration with GSK

- Seasonal flu vaccine candidate boosted antibody titers at all dose levels and for all encoded seasonal influenza strains across younger and older adults
- Potentially differentiated, multivalent candidate encodes antigens matched to all four WHOrecommended flu strains
- For influenza A strains, geometric mean titers numerically exceeded those elicited by the licensed comparator vaccines consistently across all tested dose levels and age groups
- For influenza B strains, geometric mean titers were lower than those elicited by the licensed comparator vaccines, in line with expectations and other initial mRNA-based clinical flu development programs
- Further optimizations to enhance immune responses against influenza B strains will be tested in additional Phase 2 study
- Candidate showed acceptable safety profile, confirming previous findings that the proprietary platform elicits strong overall antibody titers at well-tolerated dose levels

## **Gamaleya National Center/Sputnik**

<u>Latest News and Events</u> - No new digest announcements identified <u>https://sputnikvaccine.com/</u> - No new digest announcements identified

#### **GSK**

<u>Press releases for media</u> - No new digest announcements identified

## IMBCAMS, China

Home - Website not responding at inquiry.

#### Janssen/JNJ

<u>Press Releases</u> - No new digest announcements identified.

#### Merck

News releases - No new digest announcements identified.

#### Moderna

Press Releases - No new digest announcements identified

#### Nanogen

<u>News</u> - No new digest announcements identified

#### **Novartis**

<u>News</u> - No new digest announcements identified.

#### **Novavax**

Press Releases

Apr 1, 2024 Press release

Novavax Presents Data on Updated COVID-19 Vaccine and Progress to Date on its COVID-19-Influenza Combination Vaccine Candidate at World Vaccine Congress 2024

#### **Pfizer**

Recent Press Releases - No new digest announcements identified.

#### R-Pharm

https://rpharm-us.com/index.php

[No news or media page identified]

#### Sanofi Pasteur

Press Releases - No new digest announcements identified

#### **Serum Institute of India**

**NEWS & ANNOUNCEMENTS** 

Tuesday, April 02, 2024

<u>Bharat Biotech and Bilthoven Biologicals B.V. Announce Collaboration to Produce and Supply Oral Polio Vaccines</u>

#### Sinopharm/WIBPBIBP

<u>News</u> - No new digest announcements identified [English translation function not operating]

#### Sinovac

<u>Press Releases</u> - No new digest announcements identified.

#### **SK Biosciences**

Press Releases

#### Takeda

<u>Newsroom</u> - No new digest announcements identified.

#### Valneva

<u>Press Releases</u> - No new digest announcements identified.

## **Vector State Research Centre of Viralogy and Biotechnology**

Home - Website not responding [404 error]

## WestVac Biopharma

<u>Media</u> - No new digest announcements identified.

## Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.] <u>Website</u> [No News/Announcements page identified]

::::::

#### Contents [click to move among sections]

:: Milestones, Perspectives

:: WHO

:: Organization Announcements

:: Journal Watch

:: Pre-Print Servers

::::::

#### Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: <a href="mailto:david.r.curry@centerforvaccineethicsandpolicy.org">david.r.curry@centerforvaccineethicsandpolicy.org</a>

## **AJOB Empirical Bioethics**

Volume 15, 2023 Issue 1 <a href="https://www.tandfonline.com/toc/uabr21/current">https://www.tandfonline.com/toc/uabr21/current</a> [Reviewed earlier]

#### **AMA Journal of Ethics**

Volume 26, Number 3: E195-273 Mar 2024

## https://journalofethics.ama-assn.org/issue/critical-pedagogies-health-professions-education

## Psychiatric Inpatient Environmental Architecture

Inpatient psychiatric units designed to reduce patients' risk of harm to self or others can compromise patients' comfort. Some environmental modifications prioritize safety by limiting patients' access to personal items. This set of clinical phenomena is not ethically neutral and should prompt us to carefully consider when and how patients' experiences of their care environments undermine therapeutic goals of their hospitalizations. This theme issue investigates which criteria we should use to assess and evaluate patients' risk of harm to self or others and which values we should rely upon to guide which iatrogenic harm risks we accept as products or byproducts of clinical and organizational environmental designs.

[Reviewed earlier]

#### **American Journal of Human Genetics**

Apr 04, 2024 Volume 111 Issue 4 p621-806 https://www.cell.com/ajhg/current Editors' Corner

## Guidance on use of race, ethnicity, and geographic origin as proxies for genetic ancestry groups in biomedical publications

W. Gregory Feero, et al.

In March 2023, the National Academies of Sciences, Engineering, and Medicine (NASEM) released a consensus study report titled Using Population Descriptors in Genetics and Genomics Research.1 Sponsored by the US National Institutes of Health, the report is more than a discussion of the use of terminology; the authors of the NASEM report suggest a tectonic shift away from current models that use race, ethnicity, and geographic origin as proxies for genetic ancestry groups (i.e., a set of individuals who share more similar genetic ancestries) in genetic and genomic science.

## This Month in The Journal

Alyson B. Barnes, Kylee L. Spencer, Sara B. Cullinan

Although the detrimental effects of smoking on human health are well documented, our understanding of these effects at a molecular level remains incomplete. In recent years, many studies have identified associations between smoking and changes in DNA methylation, an epigenetic mark that modulates gene expression. Most of these analyses have utilized the most widely available biological sample: blood. In this issue, Li et al. leverage data from the Genotype-Tissue Expression (GTEx) project to explore how smoking alters DNA methylation and gene expression across a range of tissues.

#### American Journal of Infection Control

March 2024 Volume 52 Issue 3 p261-380 http://www.ajicjournal.org/current [Reviewed earlier]

#### **American Journal of Preventive Medicine**

March 2024 Volume 66 Issue 3 p389-572 <a href="https://www.ajpmonline.org/current">https://www.ajpmonline.org/current</a> [Reviewed earlier]

## **American Journal of Public Health**

March 2024 114(3)

## http://ajph.aphapublications.org/toc/ajph/current [Reviewed earlier]

## **American Journal of Tropical Medicine and Hygiene**

Volume 110 (2024): Issue 3 (Mar 2024)

https://www.ajtmh.org/view/journals/tpmd/110/2/tpmd.110.issue-3.xml

[Reviewed earlier]

#### **Annals of Internal Medicine**

March 2024 Volume 177, Issue 3 <a href="https://www.acpjournals.org/toc/aim/current">https://www.acpjournals.org/toc/aim/current</a> [Reviewed earlier]

## Artificial Intelligence - An International Journal

Volume 328 March 2024 <a href="https://www.sciencedirect.com/journal/artificial-intelligence/vol/328/suppl/C">https://www.sciencedirect.com/journal/artificial-intelligence/vol/328/suppl/C</a> [Reviewed earlier]

#### **BMC Cost Effectiveness and Resource Allocation**

http://resource-allocation.biomedcentral.com/ (Accessed 06 Apr 2024) [No new digest content identified]

## **BMC Health Services Research**

http://www.biomedcentral.com/bmchealthservres/content (Accessed 06 Apr 2024) [No new digest content identified]

#### **BMC Infectious Diseases**

http://www.biomedcentral.com/bmcinfectdis/content (Accessed 06 Apr 2024)

## An evaluation of the cost of human papilloma virus (HPV) vaccine delivery in Zambia

Human papillomavirus (HPV) is a common sexually transmitted infection and the leading cause of cervical cancer. The HPV vaccine is a safe and effective way to prevent HPV infection. In Zambia, the vaccine is q...

Authors: Moses C Simuyemba, Chitalu M Chama-Chiliba, Abson Chompolola, Aaron Sinyangwe,

Abdallah Bchir, Gilbert Asiimwe, Carla Chibwesha and Felix Masiye

Citation: BMC Infectious Diseases 2024 24:369 Content type: Research Published on: 2 April 2024

## **BMC Medical Ethics**

http://www.biomedcentral.com/bmcmedethics/content (Accessed 06 Apr 2024) [No new digest content identified]

#### **BMC Medicine**

http://www.biomedcentral.com/bmcmed/content (Accessed 06 Apr 2024) [No new digest content identified]

## **BMC Pregnancy and Childbirth**

http://www.biomedcentral.com/bmcpregnancychildbirth/content (Accessed 06 Apr 2024) [No new digest content identified]

#### **BMC Public Health**

http://bmcpublichealth.biomedcentral.com/articles (Accessed 06 Apr 2024)

Adaptation and application of the Parent Attitudes About Childhood Vaccines survey tool in the Vietnamese language: a cross-sectional study

Parental vaccine hesitancy could lead to outbreaks of vaccine-preventable diseases. Although parental vaccine hesitancy exists in the Vietnamese community, no research has directly investigated this social phe...

Authors: Bao Quy Quoc Truong, Ken Ing Cherng Ong, Akira Shibanuma, Junko Kiriya and Masamine

Jimba

Citation: BMC Public Health 2024 24:946

Content type: Research Published on: 2 April 2024

## **BMC Research Notes**

http://www.biomedcentral.com/bmcresnotes/content (Accessed 06 Apr 2024) [No new digest content identified]

#### **BMJ Evidence-Based Medicine**

April 2024 - Volume 29 - 2 https://ebm.bmj.com/content/29/2 [Reviewed earlier]

#### **BMJ Global Health**

March 2024 - Volume 9 - 3 https://gh.bmj.com/content/9/3 [Reviewed earlier]

#### **Bulletin of the Atomic Scientists**

March 2024 https://thebulletin.org/magazine/2024-03/ [Reviewed earlier]

## **Bulletin of the World Health Organization**

Volume 102(4); 2024 Apr 1

https://www.ncbi.nlm.nih.gov/pmc/issues/458786/

**Editorials** 

## <u>Three decades of progress and setbacks since the first international conference on population and development</u>

Manjulaa Narasimhan, Lale Say, Pascale Allotey

Bull World Health Organ. 2024 Apr 1; 102(4): 226-226A. Published online 2024 Apr 1.

doi: 10.2471/BLT.24.291654

PMCID: PMC10976866

#### Research

## Global vaccine coverage and childhood survival estimates: 1990-2019

Haijun Zhang, Bryan Patenaude, Haonan Zhang, Mark Jit, Hai Fang

Bull World Health Organ, 2024 Apr 1; 102(4): 276-287. Published online 2024 Feb 29.

doi: 10.2471/BLT.23.290129 PMCID: PMC10976869

#### Cell

Mar 28, 2024 Volume 187 Issue 7 p1567-1818 https://www.cell.com/cell/current 50th Anniversary

## Five decades of advances in cancer research

The Cell editorial team

Over the past 50 years, our understanding of cancer has evolved from its viral origin to a complex systemic disease. Along the way, improved diagnosis and therapeutics saved millions of lives. To mark Cell's 50th anniversary, this focus issue envisions a future where all cancers are preventable, manageable, and even curable.

#### **Child Care, Health and Development**

Volume 50, Issue 2 March 2024 <a href="https://onlinelibrary.wiley.com/toc/13652214/current">https://onlinelibrary.wiley.com/toc/13652214/current</a> [Reviewed earlier]

#### **Clinical Pharmacology & Therapeutics**

Volume 115, Issue 3 Pages: 375-626 March 2024 <a href="https://ascpt.onlinelibrary.wiley.com/toc/15326535/current">https://ascpt.onlinelibrary.wiley.com/toc/15326535/current</a> **Subcutaneous Biologics: Clinical Pharmacology and Drug Development**[Reviewed earlier]

#### **Clinical Therapeutics**

February 2024 Volume 46 Issue 2 p85-184 <a href="http://www.clinicaltherapeutics.com/current">http://www.clinicaltherapeutics.com/current</a> [Reviewed earlier]

#### **Clinical Trials**

Volume 21 Issue 1, February 2024 <a href="https://journals.sagepub.com/toc/ctja/21/1">https://journals.sagepub.com/toc/ctja/21/1</a>

#### **Conflict and Health**

http://www.conflictandhealth.com/

[Accessed 06 Apr 2024]

Attitudes, motivators, and barriers toward influenza vaccination for children: a study from a conflict-ridden country

Despite the increased recommendations for influenza vaccination, particularly among high-risk groups such as young children, Yemen lacks an influenza vaccination program, and the influenza vaccine is not inclu...

Authors: Wesam S. Ahmed, Abdulsalam M. Halboup, Arwa Alshargabi, Ahmed Al-mohamadi, Yousf

K. Al-Ashbat and Sayida Al-Jamei

Citation: Conflict and Health 2024 18:26

Content type: Research Published on: 3 April 2024

## **Contemporary Clinical Trials**

Volume 138 March 2024

https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/1387/suppl/C

[Reviewed earlier]

#### The CRISPR Journal

Volume 7, Issue 1 / February 2024 <a href="https://www.liebertpub.com/toc/crispr/7/1">https://www.liebertpub.com/toc/crispr/7/1</a> [Reviewed earlier]

#### **Current Genetic Medicine Reports**

Volume 11, issue 1-2, June 2023 <a href="https://link.springer.com/journal/40142/volumes-and-issues/11-1">https://link.springer.com/journal/40142/volumes-and-issues/11-1</a> [Reviewed earlier]

#### **Current Medical Research and Opinion**

Volume 40, Issue 3 2024 <a href="https://www.tandfonline.com/toc/icmo20/current">https://www.tandfonline.com/toc/icmo20/current</a> [Reviewed earlier]

#### **Current Opinion in Infectious Diseases**

April 2024 - Volume 37 - Issue 2 <a href="https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx">https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx</a> [Reviewed earlier]

## **Current Protocols in Human Genetics**

https://currentprotocols.onlinelibrary.wiley.com/journal/19348258 [Accessed 06 Apr 2024] [No new digest content identified]

## **Developing World Bioethics**

Volume 24, Issue 1 Pages: 1-48 March 2024

https://onlinelibrary.wiley.com/toc/14718847/current

Access to Essential Medicines for Global Health and the Human Right to Health

[Reviewed earlier]

## **Development in Practice**

Volume 34, Issue 1, 2024

http://www.tandf1nline.com/toc/cdip20/current

[Reviewed earlier]

## **Development Policy Review**

Volume 42, Issue 2 March 2024

https://onlinelibrary.wiley.com/toc/14677679/current

https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx

[Reviewed earlier]

## **Disaster Medicine and Public Health Preparedness**

Volume 18 - 2024

https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-

<u>issue</u>

[Reviewed earlier]

#### **Disasters**

Volume 48, Issue 2 April 2024

https://onlinelibrary.wiley.com/toc/14677717/2024/48/2

[Reviewed earlier]

### **EMBO Reports**

Volume 25 Issue 3 12 March 2024

https://www.embopress.org/toc/14693178/current

[Reviewed earlier]

#### **Emerging Infectious Diseases**

Volume 30, Number 4-April 2024

http://wwwnc.cdc.gov/eid/

Synopses

Medscape CME Activity

Concurrent Outbreaks of Hepatitis A, Invasive Meningococcal Disease, and Mpox,

Florida, USA, 2021-2022

## Commentaries

<u>Ten Years of High-Consequence Pathogens—Research Gains, Readiness Gaps, and Future Goals [PDF - 238 KB - 3 pages]</u>

J. H. McQuiston et al.

Online Reports

## <u>Prioritizing Mental Health within HIV and Tuberculosis Services in PEPFAR [PDF - 602 KB - 5 pages]</u>

R. Fukunaga et al

#### **Epidemics**

Volume 46 March 2024 <a href="https://www.sciencedirect.com/journal/epidemics/vol/46/suppl/C">https://www.sciencedirect.com/journal/epidemics/vol/46/suppl/C</a> [Reviewed earlier]

## **Epidemiology and Infection**

Volume 152 - 2024 <a href="https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue">https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue</a> [Reviewed earlier]

#### **Ethics & Human Research**

Volume 46, Issue 2 Pages: 1-35 March—April 2024 <a href="https://onlinelibrary.wiley.com/toc/25782363/current">https://onlinelibrary.wiley.com/toc/25782363/current</a> *Indigenous data sovereignty:: Returning clinically relevant results*[Reviewed earlier]

## **Ethics & International Affairs**

Volume 37 - Issue 4 - Winter 2023 <a href="https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue">https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue</a> [Reviewed earlier]

#### **Ethics, Medicine and Public Health**

Volume 31 (December 2023) <a href="https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/31/suppl/C">https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/31/suppl/C</a> [Reviewed earlier]

#### The European Journal of Public Health

Volume 34, Issue 2, April 2024 https://academic.oup.com/eurpub/issue/34/2 Vaccination

<u>Understanding the health system barriers and enablers to childhood MMR and HPV vaccination among disadvantaged, minority or underserved populations in middle- and high-income countries: a systematic review</u>

Jumanah Essa-Hadad and others

European Journal of Public Health, Volume 34, Issue 2, April 2024, Pages 368–374, https://doi.org/10.1093/eurpub/ckad232

<u>Political polarization may affect attitudes towards vaccination. An analysis based on the European Social Survey data from 23 countries</u>

Michał Wróblewski and Andrzej Meler

European Journal of Public Health, Volume 34, Issue 2, April 2024, Pages 375–379, <a href="https://doi.org/10.1093/eurpub/ckae002">https://doi.org/10.1093/eurpub/ckae002</a>

## <u>Multilevel analysis of COVID-19 vaccination intention: the moderating role of economic and cultural country characteristics</u>

Monika Lamot and Andrej Kirbiš

European Journal of Public Health, Volume 34, Issue 2, April 2024, Pages 380–386, <a href="https://doi.org/10.1093/eurpub/ckae022">https://doi.org/10.1093/eurpub/ckae022</a>

## **Expert Review of Vaccines**

Vol 23 (1) 2023 https://www.tandfonline.com/toc/ierv20/current [Reviewed earlier]

## **Foreign Affairs**

March/April 2024 Volume 103, Number 2 <a href="https://www.foreignaffairs.com/issues/2023/103/2">https://www.foreignaffairs.com/issues/2023/103/2</a> [Reviewed earlier]

## **Forum for Development Studies**

Volume 51, 2023 - Issue 1 <a href="http://www.tandfonline.com/toc/sfds20/current">http://www.tandfonline.com/toc/sfds20/current</a> [Reviewed earlier]

#### **Genetics in Medicines**

Volume 26, Issue 3 March 2024 <a href="https://www.sciencedirect.com/journal/genetics-in-medicine/vol/26/issue/3">https://www.sciencedirect.com/journal/genetics-in-medicine/vol/26/issue/3</a> [Reviewed earlier]

#### **Genome Medicine**

https://genomemedicine.biomedcentral.com/articles [Accessed 06 Apr 2024] [No new digest content identified]

## **Global Health Action**

Volume 17, Issue 1 (2024) <a href="https://www.tandfonline.com/toc/zgha20/current?nav=tocList">https://www.tandfonline.com/toc/zgha20/current?nav=tocList</a> [Reviewed earlier]

### **Global Health: Science and Practice (GHSP)**

Vol. 12, No. 1 February 28, 2024 <a href="http://www.ghspjournal.org/content/current">http://www.ghspjournal.org/content/current</a> [Reviewed earlier]

## Global Legal Monitor & Legal Reports - Library of Congress/USA

https://www.loc.gov/collections/global-legal-monitor/

https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date desc

[Accessed 06 Apr 2024]

#### **Article - South Korea: Digital Medical Products Act Enacted**

\_ The <u>Digital Medical Products Act</u> (Act No. 20139) was published in Gwanbo, South Korea's official gazette, on January 23, 2024. Most provisions of the act will take effect one year after the publication. (Digital Medical Products Act, Supp. Provisions art. 1.) The new act aims to secure the safety and effectiveness of digital medical products and promote quality improvement by prescribing matters necessary for handling, managing, manufacturing, and importing digital medical products. (Digital Medical Products Act art. 1.)

Main Contents of the Act

Digital medical products include digital medical devices, <u>digital convergence medicines</u>, and digital medical or health support devices. (Art. 2.) The act requires the minister of food and drug safety (MFDS) to conduct safety management of digital medical products in accordance with differences in their purpose, function, and potential risks to the human body. The MFDS is also to classify and rate digital medical products. (Art. 3.)

The MFDS is to establish and implement a comprehensive plan for digital medical product safety management every three years as well as establish an annual implementation plan. (Art. 6.)...

#### **Global Public Health**

Volume 19, Issue 1 (2024) <a href="http://www.tandfonline.com/toc/rgph20/current">http://www.tandfonline.com/toc/rgph20/current</a> [Reviewed earlier]

#### **Globalization and Health**

http://www.globalizationandhealth.com/ [Accessed 06 Apr 2024] [No new digest content identified]

## **Health and Human Rights**

Volume 25, Issue 2, December 2023 https://www.hhrjournal.org/volume-25-issue-2-december-2023/ **Special Section: Economic Inequality and the Right to Health** [Reviewed earlier]

## **Health Economics, Policy and Law**

Volume 19 - Issue 1 - January 2024 <a href="https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue">https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue</a> [Reviewed earlier]

## **Health Policy and Planning**

Volume 39, Issue 3, April 2024 https://academic.oup.com/heapol/issue/39/3 Innovation and Practice Reports

# Humanitarian—Development Nexus: strengthening health system preparedness, response and resilience capacities to address COVID-19 in Sudan—case study of repositioning external assistance model and focus

Muna Mohamed Nur and others

## **Health Research Policy and Systems**

http://www.health-policy-systems.com/content

[Accessed 06 Apr 2024]

## <u>Use of qualitative research in World Health Organisation guidelines: a document</u> analysis

Guidelines depend on effect estimates, usually derived from randomised controlled trials, to inform their decisions. Qualitative research evidence may improve decisions made but where in the process and the methods to do this have not been so clearly established. We sought to describe and appraise how qualitative research has been used to inform World Heath Organization guidance since 2020.

Authors: Melissa Taylor, Paul Garner, Sandy Oliver and Nicola Desmond

Citation: Health Research Policy and Systems 2024 22:44

Content type: Research Published on: 4 April 2024

#### **Human Gene Therapy**

Volume 35, Issue 5-6 / March 2024 <a href="https://www.liebertpub.com/toc/hum/35/5-6">https://www.liebertpub.com/toc/hum/35/5-6</a> [Reviewed earlier]

#### **Humanitarian Practice Network**

https://odihpn.org/ Featured Publications [No new digest content identified]

#### **Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 19, Issue 3, 2023 <a href="https://www.tandfonline.com/toc/khvi20/19/3?nav=tocList">https://www.tandfonline.com/toc/khvi20/19/3?nav=tocList</a> [Reviewed earlier]

#### **Immunity**

Mar 12, 2024 Volume 57 Issue 3 p401-612 <a href="https://www.cell.com/immunity/current">https://www.cell.com/immunity/current</a> [Reviewed earlier]

## **Infectious Agents and Cancer**

http://www.infectagentscancer.com/ [Accessed 06 Apr 2024] [No new digest content identified]

## **Infectious Diseases of Poverty**

http://www.idpjournal.com/content [Accessed 06 Apr 2024] [No new digest content identified]

#### **International Health**

Volume 16, Issue 2, March 2024 <a href="https://academic.oup.com/inthealth/issue/16/2">https://academic.oup.com/inthealth/issue/16/2</a> [Reviewed earlier]

## **International Human Rights Law Review**

Volume 12 (2023): Issue 2 (Dec 2023) <a href="https://brill.com/view/journals/hrlr/12/2/hrlr.12.issue-2.xml">https://brill.com/view/journals/hrlr/12/2/hrlr.12.issue-2.xml</a> Table of Contents [Reviewed earlier]

## **International Journal of Community Medicine and Public Health**

Vol. 11 No. 3 (2024): March 2024 https://www.ijcmph.com/index.php/ijcmph/issue/view/110 [Reviewed earlier]

## **International Journal of Epidemiology**

Volume 52, Issue 6, December 2023 <a href="https://academic.oup.com/ije/issue">https://academic.oup.com/ije/issue</a> [Reviewed earlier]

## **International Journal of Human Rights in Healthcare**

Volume 17 Issue 1 2024 <a href="https://www.emerald.com/insight/publication/issn/2056-4902/vol/17/iss/1">https://www.emerald.com/insight/publication/issn/2056-4902/vol/17/iss/1</a> Table of contents [Reviewed earlier]

#### **JAMA**

April 2, 2024, Vol 331, No. 13, Pages 1073-1162 https://jamanetwork.com/journals/jama/currentissue [New issue; No digest content identified]

## **JAMA Health Forum**

March 2024, Vol 5, No. 3 <a href="https://jamanetwork.com/journals/jama-health-forum/issue">https://jamanetwork.com/journals/jama-health-forum/issue</a> [Reviewed earlier]

#### **JAMA Pediatrics**

March 2024, Vol 178, No. 3, Pages 211-322

# https://jamanetwork.com/journals/jamapediatrics/currentissue [Reviewed earlier]

### **JBI Evidence Synthesis**

March 2024 - Volume 22 - Issue 3 <a href="https://journals.lww.com/jbisrir/Pages/currenttoc.aspx">https://journals.lww.com/jbisrir/Pages/currenttoc.aspx</a> [Reviewed earlier]

#### **Journal of Adolescent Health**

March 2024 Volume 74 Issue 3 p395-628 https://www.jahonline.org/current [Reviewed earlier]

### **Journal of Artificial Intelligence Research**

Vol. 79 (2024)
<a href="https://www.jair.org/index.php/jair">https://www.jair.org/index.php/jair</a>
Contents
[Reviewed earlier]

### **Journal of Community Health**

Volume 49, Issue 2 April 2024 <a href="https://link.springer.com/journal/10900/volumes-and-issues/49-2">https://link.springer.com/journal/10900/volumes-and-issues/49-2</a> [Reviewed earlier]

#### **Journal of Current Medical Research and Opinion**

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.

Vol. 7 No. 01 (2024), January 2, 2024, Page 1988-1996

<a href="https://www.cmro.in/index.php/jcmro/issue/view/75">https://www.cmro.in/index.php/jcmro/issue/view/75</a>
[New issue; No digest content identified]

#### **Journal of Development Economics**

Volume 167 March 2024 <a href="https://www.sciencedirect.com/journal/journal-of-development-economics/vol/167/suppl/C">https://www.sciencedirect.com/journal/journal-of-development-economics/vol/167/suppl/C</a> [Reviewed earlier]

# **Journal of Empirical Research on Human Research Ethics**

Volume 19 Issue 1-2, February–April 2024 <a href="http://journals.sagepub.com/toc/jre/current">http://journals.sagepub.com/toc/jre/current</a> [Reviewed earlier]

# Journal of Epidemiology & Community Health

March 2024 - Volume 78 - 3

https://jech.bmj.com/content/78/3

Sociodemographic and socioeconomic disparities in COVID-19 vaccine uptake in Belgium: a nationwide record linkage study (26 December, 2023)

Lisa Cavillot, Joris A F van Loenhout, Brecht Devleesschauwer, Chloé Wyndham-Thomas, Herman Van Oyen, Jinane Ghattas, Koen Blot, Laura Van den Borre, Matthieu Billuart, Niko Speybroeck, Robby De Pauw, Veerle Stouten, Lucy Catteau, Pierre Hubin

#### **Journal of Evidence-Based Medicine**

Volume 17, Issue 1 Pages: 1-235 March 2024 <a href="https://onlinelibrary.wiley.com/toc/17565391/current">https://onlinelibrary.wiley.com/toc/17565391/current</a> [New issue; No digest content identified]

#### **Journal of Global Ethics**

Volume 19, Issue 3 (2023) <a href="http://www.tandfonline.com/toc/rjge20/current">http://www.tandfonline.com/toc/rjge20/current</a> [Reviewed earlier]

# **Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 35, Number 1, February 2024 <a href="https://muse.jhu.edu/issue/52063">https://muse.jhu.edu/issue/52063</a> *Table of Contents*[Reviewed earlier]

# **Journal of Immigrant and Minority Health**

Volume 26, Issue 2 April 2024 https://link.springer.com/journal/10903/volumes-and-issues/26-2 [Reviewed earlier]

# Journal of Immigrant & Refugee Studies

Volume 22, 2024 \_ Issue 1 https://www.tandfonline.com/toc/wimm20/current [Reviewed earlier]

#### **Journal of Infectious Diseases**

Volume 229, Issue 3, 15 March 2024 https://academic.oup.com/jid/issue/229/3 [Reviewed earlier]

#### **Journal of International Development**

Volume 36, Issue 2 Pages: 773-1592 March 2024 <a href="https://onlinelibrary.wiley.com/toc/10991328/current">https://onlinelibrary.wiley.com/toc/10991328/current</a> [Reviewed earlier]

#### **Journal of Medical Ethics**

March 2024 - Volume 50 - 3 http://jme.bmj.com/content/current [Reviewed earlier]

#### **Journal of Patient-Centered Research and Reviews**

Volume 10, Issue 4 (2023) https://institutionalrepository.aah.org/jpcrr/ [Reviewed earlier]

#### **The Journal of Pediatrics**

Volume 266 March 2024 <a href="https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/266/suppl/C">https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/266/suppl/C</a> [Reviewed earlier]

### **Journal of Pharmaceutical Policy and Practice**

Volume 17, Issue 1 (2024) Issue 1 <a href="https://www.tandfonline.com/toc/jppp20/17/1">https://www.tandfonline.com/toc/jppp20/17/1</a> [Reviewed earlier]

# **Journal of Public Health Management & Practice**

March/April 2024 - Volume 30 - Issue 2 <a href="https://onlinelibrary.wiley.com/toc/10991328/current">https://onlinelibrary.wiley.com/toc/10991328/current</a> [Reviewed earlier]

# **Journal of Public Health Policy**

Volume 45, issue 1, March 2024 https://link.springer.com/journal/41271/volumes-and-issues/45-1 [Reviewed earlier]

#### **Journal of the Royal Society – Interface**

April 2024 Volume 21 Issue 213 <a href="https://royalsocietypublishing.org/toc/rsif/current">https://royalsocietypublishing.org/toc/rsif/current</a> [New issue; No digest content identified]

#### **Journal of Travel Medicine**

Volume 31, Issue 2, March 2024 <a href="https://academic.oup.com/jtm/issue">https://academic.oup.com/jtm/issue</a> [Reviewed earlier]

#### Journal of Virology

Volume 98 • Number 2 • February 2024 <a href="http://jvi.asm.org/content/current">http://jvi.asm.org/content/current</a> [Reviewed earlier]

#### The Lancet

Apr 06, 2024 Volume 403 Number 10434 p1309-1418, e21 https://www.thelancet.com/journals/lancet/issue/current Article

Optimised prevention of postnatal HIV transmission in Zambia and Burkina Faso (PROMISE-EPI): a phase 3, open-label, randomised controlled trial Chipepo Kankasa, et al. for the PROMISE-EPI Trial Group

The Lancet Commissions

# <u>Under threat: the International AIDS Society-Lancet Commission on Health and Human</u> Rights

Chris Beyrer, e al.

... The International AIDS Society-Lancet Commission on Health and Human Rights, launched in 2021, has studied the state of health and human rights, explored the reasons for global backtracking on health and human rights, and developed recommendations for renewing and updating the health and human paradigm at a time of major technological, political, and social transformations. The 23 Commissioners—who include health practitioners, academic experts, researchers, and civil society representatives with expertise in various disciplines, including medicine, infectious diseases, women's health, mental health, epidemiology, mathematical modelling, law, international human rights, climate, migration, history, and anthropology—reside and have expertise in a broad array of geographical regions. The Commission reviewed available evidence and developed actionable recommendations in eight different health and human rights domains (pandemics and access to essential interventions; the climate crisis and health and rights; displacement, migration, refugees, and conflict; structural racism, inequity, and discrimination against marginalised groups; sexual and reproductive health and rights; misinformation, disinformation, and the right to benefit from accurate scientific information; artificial intelligence; and the economic and commercial elements of the right to health). These domain-specific reviews were guided and informed by a socioecological model, which described the complex relationship among the factors that affect health and human rights and posited human dignity as the basis underlying all human rights. Modelling exercises were commissioned to assess the harms associated with human rights violations and the positive public health effect of various policy and programmatic innovations based on human rights approaches. Due to their cross-cutting nature, gender and criminalisation (eq, of personal drug use, one or more aspects of sex work, consensual same-sex relations) were mainstreamed across all eight thematic domains...

# The Lancet Child & Adolescent Health

Mar 2024 Volume 8 Number 3 p175-244, e2-e5 <a href="https://www.thelancet.com/journals/lanchi/issue/current">https://www.thelancet.com/journals/lanchi/issue/current</a> [Reviewed earlier]

### **Lancet Digital Health**

Mar 2024 Volume 6 Number 3 e145-e229 <a href="https://www.thelancet.com/journals/landig/issue/current">https://www.thelancet.com/journals/landig/issue/current</a> [Reviewed earlier]

#### **Lancet Global Health**

Mar 2024 Volume 12 Number 3 e341-e529 <a href="https://www.thelancet.com/journals/langlo/issue/current">https://www.thelancet.com/journals/langlo/issue/current</a>

#### [Reviewed earlier]

#### **Lancet Infectious Diseases**

Mar 2024 Volume 24 Number 3 p217-328, e137-e206 <a href="https://www.thelancet.com/journals/laninf/issue/current">https://www.thelancet.com/journals/laninf/issue/current</a> [Reviewed earlier]

# **Lancet Public Health**

Mar 2024 Volume 9 Number 3 e147-e206 <a href="https://www.thelancet.com/journals/lanpub/issue/current">https://www.thelancet.com/journals/lanpub/issue/current</a> [Reviewed earlier]

# **Lancet Respiratory Medicine**

Mar 2024 Volume 12 Number 3 p181-254, e7-e12 <a href="https://www.thelancet.com/journals/lanres/issue/current">https://www.thelancet.com/journals/lanres/issue/current</a> [Reviewed earlier]

## **Maternal and Child Health Journal**

Volume 28, Issue 3 March 2024 <a href="https://link.springer.com/journal/10995/volumes-and-issues/28-3">https://link.springer.com/journal/10995/volumes-and-issues/28-3</a> [Reviewed earlier]

# **Medical Decision Making (MDM)**

Volume 44 Issue 3, April 2024 http://mdm.sagepub.com/content/current [New issue; No digest content identified]

# The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy Volume 102, Issue 1 Pages: 1-269 March 2024 <a href="https://onlinelibrary.wiley.com/toc/14680009/current">https://onlinelibrary.wiley.com/toc/14680009/current</a> [Reviewed earlier]

# **Molecular Therapy**

Mar 06, 2024 Volume 32Issue 3 p563-856 <a href="https://www.cell.com/molecular-therapy/current">https://www.cell.com/molecular-therapy/current</a> [Reviewed earlier]

#### Nature

Volume 628 Issue 8006, 4 April 2024 https://www.nature.com/nature/volumes/627/issues/8006 [New issue; No digest content identified]

#### **Nature Biotechnology**

Volume 42 Issue 3, March 2024 https://www.nature.com/nbt/volumes/42/issues/3 [Reviewed earlier]

#### **Nature Communications**

https://www.nature.com/subjects/health-sciences/ncomms (Accessed06 Apr 2024) [No new digest content identified]

#### **Nature Genetics**

Volume 56 Issue 3, March 2024 <a href="https://www.nature.com/ng/volumes/56/issues/3">https://www.nature.com/ng/volumes/56/issues/3</a> [Reviewed earlier]

#### **Nature Human Behaviour**

Volume 8 Issue 3, March 2024 <a href="https://www.nature.com/nathumbehav/volumes/8/issues/3">https://www.nature.com/nathumbehav/volumes/8/issues/3</a> [Reviewed earlier]

#### **Nature Medicine**

Volume 30 Issue 3, March 2024 https://www.nature.com/nm/volumes/30/issues/3 [Reviewed earlier]

#### **Nature Reviews Drug Discovery**

Volume 23 Issue 3, March 2024 <a href="https://www.nature.com/nrd/volumes/23/issues/3">https://www.nature.com/nrd/volumes/23/issues/3</a> [Reviewed earlier]

#### **Nature Reviews Genetics**

Volume 25 Issue 3, March 2024 https://www.nature.com/nrg/volumes/25/issues/3 [Reviewed earlier]

# **Nature Reviews Immunology**

Volume 24 Issue 3, March 2024 <a href="https://www.nature.com/nri/volumes/24/issues/3">https://www.nature.com/nri/volumes/24/issues/3</a> [Reviewed earlier]

#### **New England Journal of Medicine**

Volume 390 No. 13 April 04, 2024 <a href="https://www.nejm.org/toc/nejm/medical-journal">https://www.nejm.org/toc/nejm/medical-journal</a> <a href="https://edi.org/toc/nejm/medical-journal">Editorials</a>

#### <u>Treating Acute Covid-19 — Final Chapters Still Unwritten</u>

R.T. Gandhi and M. Hirsch

#### **NEJM Evidence**

Volume 3 No. 4 April 2024

https://evidence.nejm.org/toc/evid/current

NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.

Original Articles

#### **Promotion of Influenza Vaccination in the Emergency Department**

R.M. Rodriguez and Others

#### **Editorials**

# An Assessment of CAR-T Cell Therapy Utilization among Racial and Ethnic Minority Patients

L.C. Hill and M. Smith

# <u>Delivery of Novel Therapies without Ensuring Equitable Access — Are Cancer Centers Putting the CART19 before the Horse?</u>

M. Charlot and G. Corbie

# **Adult Influenza Vaccination — Seizing Every Opportunity**

Z. Wiley and A. Roque Gardner

### njp Vaccines

https://www.nature.com/npjvaccines/ [Accessed 06 Apr 2024] [No new digest content identified]

#### **Pediatrics**

Volume 153, Issue 4 April 2024 https://publications.aap.org/pediatrics/issue/153/4 Articles

#### **Vaccine Effectiveness Against Long COVID in Children**

Hanieh Razzaghi, PhD, MPH; Christopher B. Forrest, MD, PhD; Kathryn Hirabayashi, MPH; Qiong Wu, PhD; Andrea J. Allen, MS

#### State-of-the-Art Review

# A Communication and Decision-Making Framework for Pediatric Precision Medicine Brittany L. Greene, MD, MA; Abby R. Rosenberg, MD, MS, MA; Jonathan M. Marron, MD, MPH Abstract

Advances in genomic testing have been pivotal in moving childhood cancer care forward, with genomic testing now a standard diagnostic tool for many children, adolescents, and young adults with cancer. Beyond oncology, the role of genomic testing in pediatric research and clinical care is growing, including for children with developmental differences, cardiac abnormalities, and epilepsy. Despite more standard use in their patients, pediatricians have limited guidance on how to communicate this complex information or how to engage parents in decisions related to precision medicine. Drawing from empirical work in pediatric informed consent and existing models of shared decision-making, we use pediatric precision cancer medicine as a case study to propose a

conceptual framework to approach communication and decision-making about genomic testing in pediatrics. The framework relies on identifying the type of genomic testing, its intended role, and its anticipated implications to inform the scope of information delivered and the parents' role in decision-making (leading to shared decision-making along a continuum from clinician-guided to parent-guided). This type of framework rests on practices known to be standard in other complex decision-making but also integrates unique features of genomic testing and precision medicine. With the increasing prominence of genomics and precision medicine in pediatrics, with our communication and decision-making framework, we aim to guide clinicians to better support their pediatric patients and their parents in making informed, goal-concordant decisions throughout their care trajectory.

#### **PharmacoEconomics**

Volume 42, Issue 3 March 2024 <a href="https://link.springer.com/journal/40273/volumes-and-issues/42-3">https://link.springer.com/journal/40273/volumes-and-issues/42-3</a> [Reviewed earlier]

# **PLoS Biology**

https://journals.plos.org/plosbiology/ (Accessed 06 Apr 2024) [No new digest content identified]

#### **PLoS Genetics**

https://journals.plos.org/plosgenetics/ (Accessed 06 Apr 2024) [No new digest content identified]

#### **PLoS Global Public Health**

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE\_NEWEST\_FIRST&filterStartDate =2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60 (Accessed 06 Apr 2024)
[No new digest content identified]

#### **PLoS Medicine**

http://www.plosmedicine.org/ (Accessed 06 Apr 2024) [No new digest content identified]

# **PLoS Neglected Tropical Diseases**

http://www.plosntds.org/ (Accessed 06 Apr 2024)

<u>Programmatic considerations and evidence gaps for chikungunya vaccine introduction in countries at risk of chikungunya outbreaks: Stakeholder analysis</u>

Megan Auzenbergs, Clara Maure, Hyolim Kang, Andrew Clark, Oliver Brady, Sushant Sahastrabuddhe, Kaja Abbas

Research Article | published 04 Apr 2024 PLOS Neglected Tropical Diseases <a href="https://doi.org/10.1371/journal.pntd.0012075">https://doi.org/10.1371/journal.pntd.0012075</a>

#### **PLoS One**

http://www.plosone.org/ [Accessed 06 Apr 2024]

<u>Spatial variations and determinants of timely completion of vaccination in Ethiopia using further analysis of EDHS 2019 data: Spatial and multilevel analysis</u>

Muluken Chanie Agimas, Aysheshim Kassahun Belew, Mekonnen Sisay, Lemlem Daniel Baffa, Moges Gashaw, Zufan Yiheyis Abriham, Esmael Ali Muhammad, Zeamanuel Anteneh Yigzaw, Berhanu Mengistu

Research Article | published 05 Apr 2024 PLOS ONE https://doi.org/10.1371/journal.pone.0301409

### **PLoS Pathogens**

http://journals.plos.org/plospathoge ns/ [Accessed 06 Apr 2024] [No new digest content identified]

# PNAS - Proceedings of the National Academy of Sciences of the United States

April 2, 2024 vol. 121 no. 14 https://www.pnas.org/toc/pnas/121/14 [New issue; No digest content identified]

#### **PNAS Nexus**

Volume 3, Issue 3, March 2024 https://academic.oup.com/pnasnexus/issue/3/3 [Reviewed earlier]

#### **Prehospital & Disaster Medicine**

Volume 39 - Issue 1 - February 2024 <a href="https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue">https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue</a> [Reviewed earlier]

#### **Preventive Medicine**

Volume 180 March 2024 <a href="https://www.sciencedirect.com/journal/preventive-medicine/vol/180/suppl/C">https://www.sciencedirect.com/journal/preventive-medicine/vol/180/suppl/C</a> [Reviewed earlier]

# **Proceedings of the Royal Society B**

27 March 2024 Volume 291 Issue 2019 <a href="https://royalsocietypublishing.org/toc/rspb/current">https://royalsocietypublishing.org/toc/rspb/current</a> [Reviewed earlier]

#### **Public Health**

Volume 228 Pages e1-e4, 1-206 (March 2024)

# https://www.sciencedirect.com/journal/public-health/vol/228/suppl/C [Reviewed earlier]

#### **Public Health Ethics**

Volume 16, Issue 3, November 2023 <a href="http://phe.oxfordjournals.org/content/current">http://phe.oxfordjournals.org/content/current</a> [Reviewed earlier]

#### **Public Health Genomics**

2024, Vol. 27, No. 1 <a href="https://karger.com/phg/issue/27/1">https://karger.com/phg/issue/27/1</a> [Reviewed earlier]

### **Public Health Reports**

Volume 139 Issue 2, March/April 2024 https://journals.sagepub.com/toc/phrg/139/2 [Reviewed earlier]

### **Qualitative Health Research**

Volume 34 Issue 4, March 2024 <a href="https://journals.sagepub.com/toc/QHR/current">https://journals.sagepub.com/toc/QHR/current</a> [Reviewed earlier]

#### **Research Ethics**

Volume 20 Issue 1, January 2024 <a href="http://journals.sagepub.com/toc/reab/current">http://journals.sagepub.com/toc/reab/current</a> [Reviewed earlier]

# **Reproductive Health**

http://www.reproductive-health-journal.com/content [Accessed 06 Apr 2024] [Reviewed earlier]

# Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

https://www.paho.org/journal/en

4 Apr 2024

Risk factors associated with severe COVID-19 outcomes in Jamaica: a cross-sectional study of national surveillance data

Original research | English |

4 Apr 2024

<u>Primary Health Care: the greatest ally in responding to the dengue epidemic in Brazil</u> Letter | Portuguese | 4 Apr 2024

# Strategies for expanding childhood vaccination in the Americas following the COVID-19 pandemic

Original research | English |

4 Apr 2024

# <u>Food insecurity and sociodemographic factors in Latin America during the COVID-19</u> pandemic

Original research | English |

1 Apr 2024

<u>Maintaining the Region of the Americas free of polio: best practices for incident management support teams</u>

Brief communication | English |

#### **Risk Analysis**

Volume 44, Issue 3 Pages: 509-737 March 2024 <a href="https://onlinelibrary.wiley.com/toc/15396924/current">https://onlinelibrary.wiley.com/toc/15396924/current</a> [Reviewed earlier]

# **Risk Management and Healthcare Policy**

https://www.dovepress.com/risk-management-and-healthcare-policy-archive56 [Accessed 06 Apr 2024] [Reviewed earlier]

#### Science

Volume 384| Issue 6691| 5 Apr 2024 https://www.science.org/toc/science/current [New issue; No digest content identified]

# **Science and Engineering Ethics**

Volume 30, Issue 2 April 2024 <a href="https://link.springer.com/journal/11948/volumes-and-issues/30-2">https://link.springer.com/journal/11948/volumes-and-issues/30-2</a> [Reviewed earlier]

#### **Science Translational Medicine**

Volume 16| Issue 741| 3 Apr 2024 https://www.science.org/toc/stm/current [New issue; No digest content identified]

# **Scientific Reports**

https://www.nature.com/srep/articles?type=article [Accessed 06 Apr 2024] [No new digest content identified]

#### **Social Science & Medicine**

Volume 346 April 2024

https://www.sciencedirect.com/journal/social-science-and-medicine/vol/346/suppl/C

[Reviewed earlier]

#### **Systematic Reviews**

https://systematicreviewsjournal.biomedcentral.com/articles

[Accessed 06 Apr 2024]

[No new digest content identified]

#### **Theoretical Medicine and Bioethics**

Volume 45, Issue 2 April 2024

https://link.springer.com/journal/11017/volumes-and-issues/45-2

[Reviewed earlier]

#### **Travel Medicine and Infectious Diseases**

Volume 58 March-April 2024

https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/58/suppl/C

[Reviewed earlier]

### **Tropical Medicine & International Health**

Volume 29, Issue 3 Pages: i-iv, 161-255 March 2024

https://onlinelibrary.wiley.com/toc/13653156/current

[Reviewed earlier]

#### Vaccine

Volume 42, Issue 9 Pages 2115-2494 (2 April 2024)

https://www.sciencedirect.com/journal/vaccine/vol/42/issue/9

Short communication Abstract only

# A community-engaged approach to translate a Vaccine Hesitancy Scale into Haitian Creole

Greta Sirek, Sciaska Ulysse, Marie Jacques Toussaint, Chisa Nosamiefan, ... Candace H. Feldman Pages 2127-2134

Review article Open access

#### **Current vaccine strategies and novel approaches to combatting Francisella infection**

Jaikin E. Harrell, Chad J. Roy, John S. Gunn, James B. McLachlan

Pages 2171-2180

Review article Abstract only

# <u>Four statistical frameworks for assessing an immune correlate of protection (surrogate endpoint) from a randomized, controlled, vaccine efficacy trial</u>

Peter B. Gilbert, Youyi Fong, Nima S. Hejazi, Avi Kenny, ... Dean Follmann Pages 2181-2190

Research article Open access

# <u>COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals</u>

K. Faksova, D. Walsh, Y. Jiang, J. Griffin, ... A. Hviid Pages 2200-2211

Research article Open access

Research atticle Open access

Region-wide assessment of National Immunization Technical Advisory Groups (NITAGs) using the NITAG Maturity Assessment Tool (NMAT) — Experience from the Eastern Mediterranean Region of the World Health Organization, 2023

Gerald Etapelong Sume, Quamrul Hasan, Abigail Shefer, Louise Henaff, ... Yvan Hutin Pages 2239-2245

Research article Abstract only

Parental willingness to accept and pay human papillomavirus vaccine for boys aged 9–14 in a metropolis area of China: Evidence for developing a vaccination strategy

Weiyu Zhou, Xiang Guo, Jia Lu, Xinyue Lu, ... Yihan Lu

Pages 2246-2253

Research article Abstract only

<u>Developing a novel screening tool to address pediatric COVID-19 vaccine hesitancy at point of care</u>

Sarah G. Yashar-Gershman, Alix T. Rosenberg, Muskaan Sawhney, Maria Fernanda Machicao, ... Henry H. Bernstein

Pages 2260-2270

Research article Open access

<u>Establishing priorities to strengthen National Immunization Technical Advisory Groups in Latin America and the Caribbean</u>

Tracy Evans-Gilbert, J. Peter Figueroa, Pablo Bonvehí, Mario Melgar, ... N. Jennifer Sanwogou Pages 2310-2316

Research article Abstract only

<u>Landscaping analysis of immunization progress and program structures in selected</u> middle income Southeast Asian countries

Jessabelle E. Basa, Ralf Clemens, Sue Ann Costa Clemens, Martin Nicholson Pages 2326-2336

# **Vaccines**

https://www.mdpi.com/journal/vaccines

[Accessed 06 Apr 2024]

Open Access Article

Socio-Demographic Factors Influencing Malaria Vaccine Acceptance for Under-Five Children in a Malaria-Endemic Region: A Community-Based Study in the Democratic Republic of Congo

by Arsene Daniel Nyalundja, Patrick Musole Bugeme, Ashuza Shamamba Guillaume, Alain Balola Ntaboba, Victoire Urbain Hatu'm, Jacques Lukenze Tamuzi, Duduzile Ndwandwe, Chinwe Iwu-Jaja, Charles S. Wivsonge and Patrick D. M. C. Katoto

Two novel vaccines against malaria are proposed as a complementary control tool to prevent and reduce Plasmodium falciparum related disease and death in under-five children from moderate to

high malaria transmission regions. The Democratic Republic of Congo (DRC) has committed to eradicate malaria

#### Value in Health

March 2024 Volume 27 Issue 3 p271-382 <a href="https://www.valueinhealthjournal.com/current">https://www.valueinhealthjournal.com/current</a> [Reviewed earlier]

# **World Development**

Volume 175 March 2024 <a href="https://www.sciencedirect.com/journal/world-development/vol/175/suppl/C">https://www.sciencedirect.com/journal/world-development/vol/175/suppl/C</a> [Reviewed earlier]

::::::

### Contents [click to move among sections]

:: Milestones, Perspectives

:: WHO

:: Organization Announcements

:: Journal Watch

:: Pre-Print Servers

::::::

#### **Pre-Print Servers**

#### **Gates Open Research**

https://gatesopenresearch.org/browse/articles [Accessed 06 Apr 2024] Selected Research [No new digest content identified]

#### medRxiv

https://www.medrxiv.org/content/about-medrxiv

[Accessed 06 Apr 2024] [Filter: All articles]

# **Medical ChatGPT – A systematic Meta-Review**

Jan Egger, Malik Sallam, Gijs Luijten, Christina Gsaxner, Antonio Pepe, Jens Kleesiek, Behrus Puladi, Jianning Li

Since its release at the end of 2022, ChatGPT has seen a tremendous rise in attention, not only from the general public, but also from medical researchers and healthcare professionals. ChatGPT definitely changed the way we can communicate now with computers. We still remember the limitations of (voice) assistants, like Alexa or Siri, that were "overwhelmed" by a follow-up question after asking about the weather, not to mention even more complex questions, which they could not handle at all. ChatGPT and other Large Language Models (LLMs) turned that in the meantime upside

down. They allow fluent and continuous conversations on a human-like level with very complex sentences and diffused in the meantime into all kinds of applications and areas. One area that was not spared from this development, is the medical domain. An indicator for this is the medical search engine PubMed, which comprises currently more than 36 million citations for biomedical literature from MEDLINE, life science journals, and online books. As of March 2024, the search term "ChatGPT" already returns over 2,700 results. In general, it takes some time, until reviews, and especially systematic reviews appear for a "new" topic or discovery. However, not for ChatGPT, and the additional search restriction to "systematic review" for article type under PubMed, returns still 31 contributions, as of March 19 2024. After filtering out non-systematic reviews from the returned results, 19 publications are included. In this meta-review, we want to take a closer look at these contributions on a higher level and explore the current evidence of ChatGPT in the medical domain, because systematic reviews belong to the highest form of knowledge in science.

# <u>Trust and transfer during the covid-19 pandemic: did digital cash transfer save lives?</u>

Gindo Tampubolon

medRxiv 2024.04.04.24305360; doi: https://doi.org/10.1101/2024.04.04.24305360

# <u>Traditional Healers' Knowledge, Attitudes, and Perceptions About Tuberculosis and Collaboration with the Conventional Health System in the Kereyu Pastoralist Area of Ethiopia: A Cross-Sectional Study</u>

Bezawi Sima, Tefera Belachew, Gunnar Bjune, Fekadu Abebe medRxiv 2024.04.04.24305249; doi: https://doi.org/10.1101/2024.04.04.24305249

#### Vaccination mitigates climate-driven disruptions to malaria control

Benjamin L. Rice, Estelle Raobson, Sylviane Miharisoa, Mahery Rebaliha, Joseph Lewinski, Hanitriniaina Raharinirina, Bryan Greenhouse, Christopher D. Golden, Gabriel A. Vecchi, Amy Wesolowski, Bryan Grenfell, C. Jessica E. Metcalf medRxiv 2024.04.02.24305230; doi: https://doi.org/10.1101/2024.04.02.24305230

# <u>"Everything created by a white man is for pagans": Understanding the Barriers to Childhood Immunization in North-Eastern and North-Western Nigeria</u>

Eno-Obong Eti, Angela Odiachi, Leanne Dougherty, Matthew Alabi, Adetayo Adetunji, Adebola Adedimeji

medRxiv 2024.03.29.24305068; doi: https://doi.org/10.1101/2024.03.29.24305068

# **OSF Pre-prints**

https://osf.io/preprints/discover?provider=OSF&subject=bepress%7 CLife%20Sciences
[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]
Preprint

# The Emerging Role of ISO 42001 Certification in Fostering the Deployment of Responsible Generative AI Healthcare Solutions

Fabio A. Thiers and Zach Harned

Date created: 2024-04-02 Date modified: 2024-04-02

**Abstract** 

The growing excitement about the potential positive impact of generative AI (GenAI) solutions in healthcare has been tempered by uncertainty on how to ensure that such solutions are deployed safely and effectively. A core issue is that the current product-centric regulatory oversight model does not apply well to a technology that adapts to the operating environment and becomes enmeshed with medical practice in a non-deterministic manner. This difficulty has led to the development of alternate approaches to foster the responsible deployment of GenAI solutions that

are focused on the organizations developing and using the technology, as they are uniquely positioned to prevent and quickly address issues as they occur. One emerging approach is via the certification with the ISO 42001 standard, which defines the structure for auditable AI Management Systems (AIMS) in organizations developing and/or deploying AI solutions. The process of ISO 42001 certification can enable healthcare organizations to build adaptive and auditable AIMS that mitigate risks while supporting the deployment of trustworthy AI. The wide adoption of ISO 42001 certification by healthcare organizations would allow for the utilization of beneficial GenAI solutions while potentially facilitating the performance of oversight functions by regulators and payers. This article introduces the ISO 42001 implementation process in healthcare organizations and describes the next steps in the operationalization of this new GenAI risk mitigation approach.

### **Wellcome Open Research**

https://wellcomeopenresearch.org/browse/articles
[Accessed 06 Apr 2024]
Selected Research
Study Protocol Open Access

# REVISED- The PRECISE-DYAD protocol: linking maternal and infant health trajectories in sub-Saharan Africa

[version 2; peer review: 2 approved with reservations] Rachel Craik, et al. and The PRECISE-DYAD Network Abstract Background

PRECISE-DYAD is an observational cohort study of mother-child dyads running in urban and rural communities in The Gambia and Kenya. The cohort is being followed for two years and includes uncomplicated pregnancies and those that suffered pregnancy hypertension, fetal growth restriction, preterm birth, and/or stillbirth.

\* \* **\*** 

#### **Think Tanks**

Brookings [to 06 Apr 2024] http://www.brookings.edu/ Research No new digest content identified.

# **Center for Global Development** [to 06 Apr 2024]

https://www.cgd ev.org/ All Research [Selected] No new digest content identified.

Chatham House [to 06 Apr 2024] https://www.chathamhouse.org/ Selected Analysis, Comment, Events No new digest content identified.

### **Council on Foreign Relations** [to 06 Apr 2024]

https://www.cfr.org/media/news-releases New Releases [Selected] No new digest content identified.

CSIS [to 06 Apr 2024]
<a href="https://www.csis.org/">https://www.csis.org/</a>
Reports [Selected]
No new digest content identified.

# **Kaiser Family Foundation** [to06 Apr 2024] https://www.kff.org/search/?post\_type=press-release Newsroom No new digest content identified.

# McKinsey Global Institute [to 06 Apr 2024]

https://www.mckinsey.com/mgi/overview

Latest Research
No new digest content identified.

## **ODI [Overseas Development Institute]** [to 06 Apr 2024]

https://odi.org/en/publications/ Publications [Selected] No new digest content identified.

#### Pew Research Center [to 06 Apr 2024]

https://www.pewresearch.org/ Latest Publications [Selected] No new digest content identified.

Rand [to 06 Apr 2024] https://www.rand.org/pubs.html Published Research [Selected] No new digest content identified.

**Urban Institute** [to 06 Apr 2024] <a href="https://www.urban.org/publications">https://www.urban.org/publications</a> **New Research Publications - Selected** 

World Economic Forum [to 06 Apr 2024] <a href="https://agenda.weforum.org/press/">https://agenda.weforum.org/press/</a>
Media [Selected]
No new digest content identified.

::::::

### **Public Consultations/Call for Inputs/Call for Papers**

No new digest content identified.

**Vaccines and Global Health: The Week in Review** is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

:::::::

Copyright GE2P2 Global Foundation 2023. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <a href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</a> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

::::::

CVEP is a program of the <u>GE2P2 Global Foundation</u> whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the <u>Bill & Melinda Gates Foundation</u>; the <u>Bill & Melinda Gates Medical Research Institute</u>, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.